Quantcast

Industry news that matters to you.  Learn more

Vermillion Announces Positive Top-Line Data from Intended Use Study for Peripheral Artery Disease (PAD)

Vermillion, Inc., a molecular diagnostics company, today announced positive top-line results from the intended use study for its peripheral artery disease (PAD) blood test, VASCLIR. The goals of the study were to validate the markers described in earlier publications (Circulation, 2007 and Vascular Medicine, 2008) and to develop and validate a biomarker panel applicable to the intended use population.

Triple-Biomarker Approach Improves Chronic Kidney Disease Prediction Accuracy

Researchers have found that a combination biomarker approach improves risk prediction for chronic kidney disease (CKD). The study, published in the Journal of the American Medical Association (JAMA), concluded that adding cystatin C to the combination of creatinine and albumin-to-creatinine ratio (ACR) measures improved the predictive accuracy for all-cause mortality and end-stage renal disease.

Intrinsic Bioprobes Launches Three New CLIA Approved Mass Spectrometry-based Tests for Proteins Implicated in Kidney Disease and Renal Failure

Intrinsic Bioprobes Inc (“IBI”) today announced the launch of its first
mass spectrometry-based protein assays for in-vitro diagnostic testing. The assays for beta-2-microglobulin, cystatin C, and retinol binding protein are performed on IBI’s MASSAY platform at the CLIA-certified and College of American Pathology (CAP) accredited diagnostic laboratory of the Institute of Genomics Medicine, UMDNJ-New Jersey Medical School.